Physician profile

Clint Gregory

Physician Assistant · Shawnee Mission, KS

NPI 1730629981

$4,884.88

in general payments reported to CMS, 2019-2025

43 companies · $1,109 in 2025

The $1,109 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,016.35

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $846.80 2021-2025
Novo Nordisk INC $686.90 2021-2025 Ozempic, Rybelsus, Wegovy
Lilly USA, LLC $594.88 2021-2025 Mounjaro, Jardiance, Zepbound
Amgen INC. $340.16 2021-2025 Evenity, Prolia, Repatha
Bayer Healthcare Pharmaceuticals INC. $274.81 2022-2025
Pfizer INC. $265.59 2021-2025
Janssen Pharmaceuticals, INC $253.61 2021-2025 Invega Sustenna, Spravato
Glaxosmithkline, LLC. $223.41 2023-2025 Trelegy Ellipta, Bexsero, Shingrix
Astrazeneca Pharmaceuticals Lp $182.52 2022-2025 Airsupra, Fasenra, Breztri
Grifols USA, LLC $89.84 2021-2024 Prolastin-C Liquid
Boehringer Ingelheim Pharmaceuticals, INC. $79.43 2022-2025
Takeda Pharmaceuticals U.S.A., INC. $68.79 2021-2024 Trintellix
Sanofi-Aventis U.S. LLC $68.24 2022-2025
Biohaven Pharmaceuticals, INC. $62.48 2021
Amarin Pharma, INC. $56.54 2021
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Merck Sharp & Dohme LLC $51.37 2021-2022
Actelion Pharmaceuticals US, INC. $51.01 2023-2025 Uptravi, Opsumit
Inspire Medical Systems, INC. $50.54 2025 Inspire
Astellas Pharma US INC $47.21 2021-2024 Veozah
Novartis Pharmaceuticals Corporation $47.04 2022-2025
Organon LLC $41.04 2023-2024 Nexplanon
Xeris Pharmaceuticals, INC. $34.20 2021
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $33.10 2025 Caplyta
Ethicon US, LLC $32.73 2023 Vicryl
Jazz Pharmaceuticals INC. $30.94 2021
Ultragenyx Pharmaceutical INC. $29.43 2021-2022
Phathom Pharmaceuticals, INC. $27.95 2025 Voquezna
Corcept Therapeutics $27.57 2025 Korlym
Upsher-Smith Laboratories LLC $26.92 2021
Abbott Laboratories $24.04 2025 Freestyle Libre 3
Averitas Pharma INC. $23.58 2023 Qutenza
Gilead Sciences, INC. $22.22 2022
Biohaven Pharmaceutical Holding Company Ltd. $22.17 2022
Acadia Pharmaceuticals INC $22.09 2024 Daybue
Aimmune Therapeutics, INC. $22.02 2025 Zenpep
Boston Scientific Corporation $17.62 2022
Axsome Therapeutics, INC. $16.97 2025 Auvelity
Biogen, INC. $16.69 2021
Exact Sciences Corporation $16.26 2025 Cologuard Collection Kit
Lundbeck LLC $15.75 2025 Rexulti
Radius Health, INC. $15.59 2025 Tymlos
Neos Therapeutics, Lp $13.09 2024 Adzenys Xr-Odt
E.R. Squibb & Sons, L.L.C. $11.74 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Clint Gregory

$4,884.88

in general payments reported 2019-2025

Years
2021-2025
Top company
Abbvie INC.
Context
The $1,109 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).

https://glasscript.com/doctor/11053562/clint-gregory

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.